ECTRIMS 2021 | Prognostic factors in NMOSD: age, ethnicity, and relapse history
Dalia Rotstein, MD, MPH, St. Michael’s Hospital and the University of Toronto, Toronto, ON, discusses prognostic factors in neuromyelitis optica spectrum disorder (NMOSD). Early prognostication is key to developing an individualized treatment approach for optimal outcomes and thus, there is a clear need to define evidence-based prognostic measures for NMOSD. Identifying biomarkers is a major area of research in the space. Dr Rotstein discusses clinical and demographic factors associated with disease course that are beginning to come to light. Data is limited and more investigation is needed to help guide therapy in the future. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.
Disclosures
Dr Dalia Rotstein has received research support from the MS Society of Canada, Consortium of Multiple Sclerosis Centers, and Roche Canada. She has received speaker or consultant fees from Alexion, Biogen, EMD Serono, Novartis, Roche and Sanofi Aventis.
